Procalcitonin as a biomarker for ventilator associated pneumonia in COVID-19 patients: Is it an useful stewardship tool?

Ventilator associated pneumonia(VAP) is a severe complication that can lead to high mortality when not early identified or when therapy is delayed. The aim of this study was to evaluate procalcitonin(PCT) as a biomarker for VAP development. In total, 73 hospitalized patients with COVID-19 were analy...

Descripción completa

Detalles Bibliográficos
Autores principales: Côrtes, Marina Farrel, de Almeida, Bianca Leal, Espinoza, Evelyn Patricia Sanchez, Campos, Aléia Faustina, do Nascimento Moura, Maria Luiza, Salomão, Matias C., Boszczowski, Icaro, Freire, Maristela Pinheiro, de Carvalho, Laina Bubach, Paranhos-Baccalà, Gláucia, Costa, Silvia Figueiredo, Guimarães, Thaís
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Clinical Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7879055/
https://www.ncbi.nlm.nih.gov/pubmed/34243136
http://dx.doi.org/10.1016/j.diagmicrobio.2021.115344
Descripción
Sumario:Ventilator associated pneumonia(VAP) is a severe complication that can lead to high mortality when not early identified or when therapy is delayed. The aim of this study was to evaluate procalcitonin(PCT) as a biomarker for VAP development. In total, 73 hospitalized patients with COVID-19 were analyzed. PCT levels greater than 0.975ng/mL were more related to VAP. No association was found for C-reactive protein (CRP). The results show that procalcitonin may be a pertinent biomarker for VAP diagnosis and can be a helpful tool for antibiotic withdrawal.

Ejemplares similares